Literature DB >> 31548115

Prior Knee Arthroscopy Is Associated With Increased Risk of Revision After Total Knee Arthroplasty.

Alex Gu1, Michael-Alexander Malahias2, Jordan S Cohen3, Shawn S Richardson4, Seth Stake5, Jason L Blevins4, Peter K Sculco2.   

Abstract

BACKGROUND: Knee arthroscopy (KA) is frequently performed to provide improved joint function and pain relief. However, outcomes following total knee arthroplasty (TKA) after prior KA are not fully understood. The purpose of this study is to determine the relationship between prior KA within 2 years of TKA on revision rates after TKA.
METHODS: Data were collected from the Humana insurance database using the PearlDiver Patient Records Database from 2006 to 2017. Subjects were identified using Current Procedural Terminology and International Classification of Diseases procedure codes to identify primary TKA. Patients were stratified into 2 groups based upon a history of prior KA. Univariate and multivariate analyses were conducted to determine association between KA and outcomes at 2-year postoperative period.
RESULTS: In total, 138,019 patients were included in this study, with 3357 (2.4%) patients receiving a KA before TKA and 134,662 (97.6%) patients who did not. The most common reason for KA was osteoarthritis (40.0%), followed by medial tear of the meniscus (26.0%) and chondromalacia (21%.0). After adjustment, prior KA was associated with increased revision rate (odds ratio [OR], 1.392; P = .003), postoperative stiffness (OR, 1.251; P = .012), periprosthetic joint infection (OR, 1.326; P < .001), and aseptic loosening (OR, 1.401; P = .048).
CONCLUSION: Prior KA is significantly associated with increased 2-year TKA revision rate. The most common etiology for arthroscopy was osteoarthritis. The results of the study, showing that arthroscopy before TKA substantially increases the rates of revision, PJI, aseptic loosening, and stiffness, lend further credence to the idea that patients may be better served by nonsurgical management of their degenerative pathology until they become candidates for TKA. Subjecting this population to arthroscopy appears to offer limited benefit at the cost of poorer outcomes when they require arthroplasty in the future. LEVEL OF EVIDENCE: Level III therapeutic study.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  knee arthroscopy; nationwide insurance database; pearldiver; revision knee arthroplasty; total knee arthroplasty

Year:  2019        PMID: 31548115     DOI: 10.1016/j.arth.2019.08.043

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  6 in total

1.  Remarks on Some Relevant Recent Reflections about Revision Total Knee Arthroplasty.

Authors:  E Carlos Rodriguez-Merchan
Journal:  Arch Bone Jt Surg       Date:  2022-03

2.  Total knee arthroplasty after a prior knee arthroscopy has higher complication rates: a systematic review.

Authors:  Tarun Goyal; Sujit Kumar Tripathy; Alexander Schuh; Souvik Paul
Journal:  Arch Orthop Trauma Surg       Date:  2021-09-20       Impact factor: 2.928

3.  Decreased Implant Survival is Associated With Younger Patients Undergoing Total Knee Arthroplasty.

Authors:  Alex J Anatone; Shawn S Richardson; Cynthia A Kahlenberg; Elizabeth B Gausden; Mark P Figgie; Jason L Blevins
Journal:  HSS J       Date:  2021-04-14

4.  When can total knee arthroplasty be safely performed following prior arthroscopy?

Authors:  Jin-Ning Ma; Xiao-Lin Li; Pan Liang; Sheng-Li Yu
Journal:  BMC Musculoskelet Disord       Date:  2021-01-04       Impact factor: 2.362

5.  The rate of unnecessary interventions for the management of knee osteoarthritis: a population-based cohort study.

Authors:  Jacquelyn D Marsh; Ryan Degen; Trevor B Birmingham; J Robert Giffin; Alan Getgood; Robert Litchfield; Kevin Willits; J Andrew McClure; Blayne Welk
Journal:  Can J Surg       Date:  2022-02-18       Impact factor: 2.089

6.  Association Between Bio-Fermentation Derived Hyaluronic Acid and Healthcare Costs Following Knee Arthroplasty.

Authors:  Mathew Nicholls; Faizan Niazi; Winnie W Nelson; Edmund Lau; Steven M Kurtz; Kevin L Ong
Journal:  Clinicoecon Outcomes Res       Date:  2022-08-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.